Airway Inflammation in Children With Allergic Rhinitis and Intervention

Type of study :

This is a prospective randomized,double-blind, placebo-controlled study , to clarity whether treating upper airway with intranasal corticosteroids in children with allergic rhinitis may bring favors in reducing elevated lower airway inflammation，improving airway reactivity and airway resistance.

Methods :

The children with allergic rhinitis accompanied lower airway inflammation such as elevated percentage of eosinophil in induced sputums and/or higher level of fractional exhaled nitric oxide(FeNO) are recruited.By using a random digit table, eligible subjects were randomized into one of two groups,to receive budesonide nasal spray (BUD group) or nasal placebo(placebo group), 1 spray/nostril, 2 times/day, for three consecutive months observation. The following measurements were performed: skin prick test (SPT), peripheral blood cells five-classification test, serum total immunoglobulin E (IgE) and specific IgE of common inhalant allergens testing, nasal lavage and inflammatory cells classification ，pulmonary function test, bronchial provocation test，airway resistance measured by impulse oscillation technique. Meanwhile,history of all subjects were collected, visual analogue scale，rhinitis symptoms scores and rhinoconjunctivitis quality of life questionnaire (RQLQ) scores were evaluated. Symptom scores and laboratory examinations are performed at baseline,4 w,8w and 12 w after treatment.

Inclusion criteria

• clinical diagnosis of allergic rhinitis without asthma
• sensitized to more than 1 common aeroaller¬gens
• FeNO >20ppb and/or induced sputum Eosinophil>2.5%

Exclusion criteria

• Respiratory infection 2 weeks prior to initial visit
• children with nasal polyposis
• History of immunotherapy
• unable to complete the test or had limited understanding
• Use of systemic corticosteroids 4 weeks prior to initial visit
• nasal and inhaled corticosteroids 2 weeks prior to initial visit
• leukotriene receptor antagonists 2 weeks prior to initial visit
• Use of antihistamines 7 days prior to initial visit